Pharmacovigilance legislation

By -


The new pharmacovigilance legislation, which came into effect in July 2012, was the biggest change to the regulation of human medicines in the European Union (EU) since 1995. It had significant implications for applicants and holders of EUmarketing authorizations, as well as for patients, healthcare professionals and regulators.

Background to the pharmacovigilance legislation:

The development of the pharmacovigilance legislation was based on the observation that adverse drug reactions (ADRs), ‘noxious and unintended’ responses to a medicine, caused around 197,000 deaths per year in the EU.
Because of this, in 2005 the European Commission began a review of the European system of safety monitoring including sponsoring an independent study, as well as extensive public consultation through 2006 and 2007.

This process resulted in the adoption of new Directive and Regulation by the European Parliament and Council of Ministers in December 2010, bringing about significant changes in the safety monitoring of medicines across the EU:


Aims of the pharmacovigilance legislation:

The pharmacovigilance legislation aims to reduce the number of ADRs in the EU. It aims to achieve this through:
  • the collection of better data on medicines and their safety;
  • rapid and robust assessment of issues related to the safety of medicines;
  • effective regulatory action to deliver safe and effective use of medicines;
  • empowerment of patients through reporting and participation;
  • increased levels of transparency and better communication.
The legislation impacts on marketing-authorisation applicants and holders. It aims to:
  • make their roles and responsibilities clear;
  • minimise duplication of effort;
  • free up resources by rationalising and simplifying reporting on safety issues;
  • establish a clear legal framework for post-authorisation monitoring.
Full details on the initiatives introduced by the legislation and their implications are available 

Why do we need pharmacovigilance?

Many of the challenges in safety monitoring of medicines stem from the limited amount of information available from clinical trials at the time of authorisation of a medicine. Regulators have to strike a balance between making new medicines available for use in patients as early as possible and waiting until sufficient information on a product's quality, safety and efficacy is known.
Patients in clinical trials are selected carefully and followed up very closely under controlled conditions.
After authorisation, however, patients using a medicine may have other diseases and may be taking other medicines. It will also be used in a larger number of patients, raising the possibility that rare side effects could start to be seen only once the medicine is being used. Some side effects may only start to emerge once a medicine has been used for a long time.
By continuing to collect information once a medicine is available and taking action in response, regulators can continue to protect the public from emerging safety issues throughout a medicine's life cycle, thereby ensuring its safe and effective use.

Role of the European Medicines Agency

The European Medicines Agency, the EU Member States and the European Commission are responsible for implementing and operating much of the pharmacovigilance legislation. The Agency plays a key role in coordinating activities relating to the authorisation and supervision of medicines, including safety monitoring, across this network.
The Agency is working with a wide range of stakeholders including the European Commission, pharmaceutical companies, national medicines regulatory authorities, patients and healthcare professionals to ensure effective implementation and operation of the pharmacovigilancelegislation.

Comments

Post a Comment

Popular posts from this blog

Cleaning Validation | Campaign Cleaning Validation (CCV)

By -
Image
When the product demand does not allow for a complete clean up after each batch, a campaign cleaning validation must be conducted.   A back to back cleaning is performed between batches in a campaign, and a complete cleaning at the end of a campaign. Sampling of the equipment is performed after the last batch in a campaign, and all test results must meet predetermined acceptance criteria as per campaign cleaning validation protocol.   Samples for residual active may be taken after back to back cleanings where possible, for information only . Microbiology samples may be taken after back to back cleanings in a campaign to ensure that there is no excessive microbial growth on the equipment.
Read more

Western blot | troubleshooting | samples turn yellow and precipitate

By -
Image
Why western Blot samples turn yellow and precipitate? Sample appears to be acidic. Bromophenol blue in the loading buffer turns to yellow at acidic pH (below 3). Try to adjust the pH by adding NaOH [ 1 ].  Reason for that is proteins may be getting degraded due to heat exposure. One researcher had the same problem and so instead of keeping samples at 95 ° c  he started warming at 60-65 °  C. So anyone can try it out and as [ 1 ] said check the pH as well of the loading dye [ 2] .  Heating a sample also changes pH. An altered pH is not only responsible to turn the sample color yellow, but may also precipitate the proteins. Keeping SDS containing samples in ice is another common mistake to see this precipitation [ 3 ].  Another researcher said that he has got to do more with the total protein concentration in the lysate. He faced the same problem of precipitation upon denaturation at 100 ° c . He added 1/10th volume of 10% SDS and then boiled. Protein did not precipitate. T
Read more

Blending | Effective Sampling During Process Validation | Optimize Sampling Location

By -
Image
Important of sampling during blending: Sampling plays a great role in achieving the accurate results of analysis. Sampling must and procedure must be defined in validation protocols and training should be provided to the concerned staff before the validation activities start. Samples are representative of the whole batch. So it should be handled and weight carefully because segregation may occur during weighing and transpiration. Sample quantity should not be more than the required and whole mass sample should be used in the analysis. Fig: Blending Machine Sampling for blend: Blends are tested for their homogeneity. Homogeneity of the blend is critical for the quality of the final product. The sample should be taken from at least 10 locations in the blender. The sampling location should be selected according to the difficulty of the blending. Ares of poor blending must be covered in sampling. Corners and discharged point must have sampling location.
Read more